Download PDFs of the full report and individual sections
- Annual Report 2022 (PDF - 15.0MB)
- Strategic report 2022 (PDF - 10.5MB)
- Responsible business 2022 (PDF - 1.7MB)
- Corporate governance report 2022 (PDF - 1,000.4KB)
- Remuneration report 2022 (PDF - 1.0MB)
- Financial statements 2022 (PDF - 1.8MB)
- Investor information 2022 (PDF - 1,016.9KB)
- Cautionary statement 2022 (PDF - 66.1KB)
- Annual Report 2022 iXBRL viewer
- Annual Report 2022 ESEF (ZIP - 13.5MB)
- 20-F 2022 (PDF - 4.1MB)
- 20-F 2022 amendment 1 (PDF - 83.6KB)
Ahead Together
2022 was a landmark year for GSK. Following the demerger of our consumer healthcare business to form Haleon in July, we are now a fully focused biopharma company.
2022 performance and key performance indicators
Financial performance
We delivered a step-change in commercial execution with growth across the portfolio. Prioritised investment and cost discipline supported strong growth in operating profit and earnings per share (EPS).
Research and development
We continued to strengthen the late-stage pipeline with regulatory approvals, positive data read-outs and strategic business development.
Responsible business
We continue to be recognised for our environmental and sustainability leadership. Our ESG Performance Rating KPI is on track based on 83% of all performance metrics being met or exceeded. The metrics cover our six new focus areas: access to healthcare, global health and health security, environment, diversity, equity and inclusion, ethical standards, and product governance.
Culture
Culture progress KPI – ambitious for patients, accountable for impact and do the right thing – is measured through our employee surveys.
Our employee engagement score was 81% in 2022 compared to 78% in 2021.
Our business model
Our ambition is to positively impact the health of 2.5 billion people by the end of 2030. We aim to do this by developing transformational vaccines and medicines and making them available at responsible prices that are accessible for patients and sustainable for our business.
Central to our success are our people
69,400
GSK people
>80
countries worldwide
24,000
suppliers working directly with GSK
£5.5bn
R&D investment in 2022 up by 9% at AER, 4% at CER
37
manufacturing sites
4
global R&D centres
Identifying, researching, developing, testing, manufacturing and commercialising
Vaccines
We deliver one and a half million doses of our vaccines every day; and around 40% of the world’s children receive a GSK vaccine each year.
Specialty Medicines
Our portfolio of specialty medicines prevent and treat diseases, from HIV and respiratory diseases, to immuno-inflammation diseases like lupus, to cancer. Many are first or best-in-class.
General Medicines
Our portfolio of more than 150 products encompasses all of GSK’s primary care medicines, supplied in 112 countries worldwide.
Products that improve the health of millions of people in our key therapeutic areas
Infectious diseases
We are a world leader in infectious diseases, like shingles and meningitis, which, including HIV, account for two-thirds of the vaccines and medicines in our pipeline.
HIV
Our goal is to minimise the impact of HIV on people’s lives through treatment, prevention and ultimately cure.
Immunology/respiratory
We’re unlocking the science of the immune system to understand how it reacts to diseases like lupus, eosinophilic asthma and other inflammatory diseases.
Oncology
Our emerging portfolio in oncology will potentially bring new cancer therapies to the patients who need them most.
Steered by our long-term priorities
Innovation
We develop new medicines and vaccines where they are needed, with better, faster and smarter R&D. We’re combining the power of genetic and genomic insights into the causes of disease, with the speed and scale of artificial intelligence and machine learning.
Performance
We've made commitments to growth and a significant step-change in delivery. We are confident in our ability to sustain growth through the decade and beyond.
Trust
We deliver our strategy responsibly: always considering the ESG impacts of everything we do from lab to patient, helping to build trust with our stakeholders, reduce risk to our operations and deliver positive social impact.
Creating value
Patients
2.3bn packs of medicines and doses of vaccines delivered
Shareholders
61.25p per share dividend
Society
£1.3bn corporation tax paid; in addition we pay duties, levies, transactional and employment taxes
Our people
All of our people are supported to grow, be well and do work that really matters.
Reinvestment
The returns we make enable us to reinvest in discovering and developing new vaccines and medicines so we can continue getting ahead of disease.
